<DOC>
	<DOCNO>NCT00395200</DOCNO>
	<brief_summary>Hypothesis : Intravenous administration bone marrow-derived autologous adult human mesenchymal stem cell safe novel therapeutic approach patient multiple sclerosis . Mesenchymal Stem Cells Multiple Sclerosis ( MSCIMS ) phase I/IIA trial design establish safety intravenous administration bone marrow-derived autologous adult human mesenchymal stem cell patient multiple sclerosis .</brief_summary>
	<brief_title>Mesenchymal Stem Cells Multiple Sclerosis ( MSCIMS )</brief_title>
	<detailed_description>Disease investigation : Multiple Sclerosis Phase : I/IIA Number patient : 10 Design : 18 month cross , single treatment 6 month Intervention : Administration bone marrow-derived autologous mesenchymal stem cell Route administration : Intravenous Dose : Up 2,000,000 Mesenchymal Stem Cells per kilogram Source patient : Referrals accept Neurologists East Anglia North London , UK Referral Criteria : ( 3 require ) 1 . Clinically definite multiple sclerosis 2 . Expanded Kurtzke Disability Status Score 2.0 - 6.5 ( inclusive ) 3 . Evidence optic nerve damage - history optic neuritis , - relative afferent pupillary defect , - optic atrophy fundoscopy , - abnormal visual evoke potential either eyes suggestive demyelination Primary Objective : Establish safety intravenously administer bone marrow-derived autologous mesenchymal stem cell dose 2,000,000 cells/kg 12 month monitor adverse reaction . Secondary Objectives : Explore efficacy intravenously administer bone marrow-derived autologous mesenchymal stem cell dose 2,000,000 cells/kg 12 month visual function clinical , neurophysiological , imaging assessment . Outcome Measures : 1 . Primary - Adverse event 2 . Secondary - Visual function ( acuity colour ) - Visual evoked potential latency - Optic nerve Magnetisation Transfer Ratio - Retinal nerve fibre layer thickness ( optical coherence tomography ) - Brain lesion Magnetisation Transfer Ratio - MRI brain T1 hypointensity load - T cell response suppression 3 . Tertiary - Multiple Sclerosis Functional Composite Score - Expanded Kurtzke Disability Status Score</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Clinically definite multiple sclerosis Expanded Kurtzke Disability Status Score 2.0 6.5 ( inclusive ) Evidence optic nerve damage : history optic neuritis , relative afferent pupillary defect , optic atrophy fundoscopy , abnormal visual evoke potential either eyes suggestive demyelination Prolonged visual evoked potential P100 latency preserve waveform T2 lesion MRI optic nerve Retinal nerve fibre layer thickness optical coherence tomography &gt; 40 micron Age &lt; 18 year Age &gt; 65 year Patient lack capacity give inform consent Presence severe bleed disorder Planning pregnancy trial period Current MS disease modify therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Safety</keyword>
	<keyword>Therapeutics</keyword>
	<keyword>Mesenchymal Stem Cells</keyword>
	<keyword>Multipotent Mesenchymal Stromal Cells</keyword>
	<keyword>Optic Neuritis</keyword>
</DOC>